Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been given an average recommendation of “Buy” by the ten analysts that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and four have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $11.50.

Several equities research analysts have weighed in on CATX shares. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, November 11th. BTIG Research assumed coverage on shares of Perspective Therapeutics in a research report on Friday, October 10th. They set a “buy” rating and a $14.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a report on Friday, October 3rd. UBS Group reiterated a “buy” rating and issued a $7.00 price objective (down from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. Finally, B. Riley reduced their target price on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th.

Perspective Therapeutics Trading Up 5.0%

CATX opened at $2.52 on Wednesday. The company has a current ratio of 8.66, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $2.88 and its 200 day moving average price is $3.30. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $5.39.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.21 million. Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%. Equities research analysts predict that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently added to or reduced their stakes in CATX. HighTower Advisors LLC lifted its position in shares of Perspective Therapeutics by 13.2% during the 1st quarter. HighTower Advisors LLC now owns 201,586 shares of the company’s stock valued at $429,000 after acquiring an additional 23,475 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Perspective Therapeutics by 6.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company’s stock worth $925,000 after purchasing an additional 27,119 shares during the period. Affinity Asset Advisors LLC raised its position in shares of Perspective Therapeutics by 71.1% during the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock worth $4,738,000 after purchasing an additional 924,196 shares during the period. Nuveen LLC purchased a new stake in shares of Perspective Therapeutics during the first quarter valued at $2,647,000. Finally, Taylor & Morgan Wealth Management LLC boosted its position in shares of Perspective Therapeutics by 4.4% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 94,000 shares of the company’s stock valued at $323,000 after purchasing an additional 4,000 shares during the period. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.